About: The potential of anti‐infectives and immunomodulators as therapies for asthma and asthma exacerbations

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The potential of anti‐infectives and immunomodulators as therapies for asthma and asthma exacerbations Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The potential of anti‐infectives and immunomodulators as therapies for asthma and asthma exacerbations
Creator	Khaitov, Musa Skevaki, \| Moscow, Russia Edwards, M Feleszko, \| Jackson, \| Jartti, \| Johnston, \| Khaitov, \| Makrinoti, \| Nikonova, \| Schwarze, \| Sera, Shilovskiy, \| Walton, \|
Source	Medline; PMC
abstract	Asthma is responsible for approximately 25,000 deaths annually in Europe despite available medicines that maintain asthma control and reduce asthma exacerbations. Better treatments are urgently needed for the control of chronic asthma and reduction in asthma exacerbations, the major cause of asthma mortality. Much research spanning >20 years shows a strong association between microorganisms including pathogens in asthma onset, severity and exacerbation, yet with the exception of antibiotics, few treatments are available that specifically target the offending pathogens. Recent insights into the microbiome suggest that modulating commensal organisms within the gut or lung may also be a possible way to treat/prevent asthma. The European Academy of Allergy & Clinical Immunology Task Force on Anti‐infectives in Asthma was initiated to investigate the potential of anti‐infectives and immunomodulators in asthma. This review provides a concise summary of the current literature and aimed to identify and address key questions that concern the use of anti‐infectives and both microbe‐ and host‐based immunomodulators and their feasibility for use in asthma.
has issue date	2017-08-10(xsd:dateTime)
bibo:doi	10.1111/all.13257
bibo:pmid	28722755
has license	no-cc
sha1sum (hex)	c5c4ceb7f72af12592d81b9728ae1a839b7add3b
schema:url	https://doi.org/10.1111/all.13257
resource representing a document's title	The potential of anti‐infectives and immunomodulators as therapies for asthma and asthma exacerbations
has PubMed Central identifier	PMC7159495
has PubMed identifier	28722755
schema:publication	Allergy
resource representing a document's body	covid:c5c4ceb7f72af12592d81b9728ae1a839b7add3b#body_text
is schema:about of	named entity 'RESPONSIBLE' named entity 'microbiology' named entity 'infection' named entity 'asthma' named entity 'pathogen' named entity 'asthma' named entity 'asthma' named entity 'endophenotype' named entity 'asthma' named entity 'microbes' named entity 'antivirals' named entity 'immune responses' named entity 'Anti-infectives' named entity 'chemokines' named entity 'asthma' named entity 'clinical trials' named entity 'adjunctive therapy' named entity 'TLRs' named entity 'significant evidence' named entity 'animal studies' named entity 'viruses' named entity 'asthma' named entity 'Vitamin' named entity 'inoculated' named entity 'RSV' named entity 'probiotic' named entity 'MMR' named entity 'preclinical' named entity 'microbiome' named entity 'naturally occurring' named entity 'brincidofovir' named entity 'secondary endpoints' named entity 'microbe' named entity 'asthma' named entity 'respiratory tract' named entity 'ARI' named entity 'nucleoside analogue' named entity 'neutrophilic' named entity 'antibiotics' named entity 'antibody' named entity 'pathogens' named entity 'zanamivir' named entity 'wheezing' named entity 'secondary prevention' named entity 'virologically confirmed' named entity 'pertussis vaccination' named entity 'agonists' named entity 'wheezing' named entity 'Neutralizing antibodies' named entity 'allergic asthma' named entity 'Anti-infectives' named entity 'placebo' named entity 'wild-type' named entity 'randomized, double-blind' named entity 'pathogens' named entity 'ARIs' named entity 'microbiome' named entity 'hepatitis' named entity 'lymphocyte' named entity 'asthma' named entity 'wheezing' named entity 'asthmatics' named entity 'cohort study' named entity 'Antibiotics' named entity 'meta-analyses' named entity 'antibiotics' named entity 'clinical trials'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software